Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Pre-Mkt 05-13 04:56:02 EDT

510.26

+13.23

+2.66%

High511.11	Low490.13	Vol235.03K
Open494.06	D1 Closing497.03	Amplitude4.22%
Mkt Cap11.76B	Tradable Cap5.61B	Total Shares23.06M
T/O118.21M	T/O Rate2.14%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":510.26,"timestamp":1778616000000,"preClose":497.03,"halted":0,"volume":235034,"delay":0,"changeRate":0.02661811158280188,"floatShares":11000087,"shares":23055522,"eps":-13.648958,"marketStatus":"Pre-Mkt","change":13.23,"latestTime":"05-13 04:56:02 EDT","open":494.06,"high":511.11,"low":490.13,"amount":118209936.64016,"amplitude":0.042211,"askPrice":529,"askSize":100,"bidPrice":205.1,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-13.648958,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778679000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":510.26,"postHourTrading":{"tag":"盘后","latestPrice":510.26,"preClose":510.26,"latestTime":"19:48 EDT","volume":17296,"amount":8825481.6278,"timestamp":1778629701952,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5959334311539676,"impliedVol":0.2767,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2634750024","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2634750024","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634750024?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:12","pubTimestamp":1778465576,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDGL","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634926044","title":"How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634926044","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634926044?lang=en_us&edition=fundamental","pubTime":"2026-05-09 14:42","pubTimestamp":1778308975,"startTime":"0","endTime":"0","summary":"In the first quarter of 2026, Madrigal Pharmaceuticals reported a net loss of US$94.39 million as Rezdiffra generated US$311.3 million in revenue and the company broadened its MASH pipeline, including licensing Arrowhead’s clinical-stage siRNA asset ARO‑PNPLA3.\nBy pairing blockbuster-level Rezdiffra sales with an expanded portfolio of genetic and metabolic MASH candidates, Madrigal is shifting from a single‑drug story toward a broader, combination-focused franchise in liver disease.\nWe’ll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/how-blockbuster-rezdiffra-sales-and-aropnpla3-licensing-will","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/how-blockbuster-rezdiffra-sales-and-aropnpla3-licensing-will","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434573","title":"Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434573?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:55","pubTimestamp":1778234127,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00. Accordi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633307174","title":"Madrigal grants inducement equity awards to 47 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633307174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633307174?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:27","pubTimestamp":1778185675,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted May 1, 2026 equity inducement awards to 47 new non-executive employees under its 2025 Inducement Plan.Awards totaled options for 5,312 shares, 17,589 time-based restricted stock units, and 1,839 performance-based restricted stock units.Options carry an exercise price of USD 513.72; 25% vest on first anniversary of grant date, remaining shares vest 6.25% each quarter.Time-based restricted stock units vest in four equal annual installments; performance-based restricted stock units are tied to relative total shareholder return over three years with potential cliff vesting in Q1 2029.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLcc74NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","MDGL","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633262241","title":"Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633262241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633262241?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:54","pubTimestamp":1778165640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 10:54 ET (14:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149751","title":"Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149751?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:38","pubTimestamp":1778153885,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $640.00. Devarako...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633397143","title":"Madrigal Pharmaceuticals Inc : Clear Street Raises Target Price to $680 From $533","url":"https://stock-news.laohu8.com/highlight/detail?id=2633397143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633397143?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:53","pubTimestamp":1778151231,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118276","title":"Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118276","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118276?lang=en_us&edition=fundamental","pubTime":"2026-05-07 15:31","pubTimestamp":1778139071,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $311.34M, consensus $300.92M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “2026 is off to a terrific start. Rezdif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-reports-q1-eps-3-25-consensus-4-14-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-reports-q1-eps-3-25-consensus-4-14-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633165004","title":"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633165004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633165004?lang=en_us&edition=fundamental","pubTime":"2026-05-07 07:00","pubTimestamp":1778108421,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and Pennant Group (P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-and-pennant-group-pntg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-and-pennant-group-pntg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4137","PNTG","BK4196","XLV","MDGL","LU0029874061.USD","LU0128526141.USD","BK4581","BK4139","BK4185","LABU","BK4585","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434134","title":"BUZZ-Madrigal Pharma rises after Q1 revenue beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434134?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:46","pubTimestamp":1778078806,"startTime":"0","endTime":"0","summary":"BUZZ-Madrigal Pharma rises after Q1 revenue beat** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O rise 5.3% to $529.08** Co posts Q1 revenue of $311.3 million, above analysts' estimate of $300.8 million, according to LSEG data** Rezdiffra - MDGL's only marketed drug for a fatty liver disease called MASH - accounted for all Q1 revenue, with sales up 127% year-over-year** Co says more than 42,250 patients were on Rezdiffra as of March 31, up about 2.5 times from a year earlier** \"We continue to have conviction in the MASH market size, and see MDGL shares as undervalued relative to other mid cap biotechs,\" Barclays says ** Including session's move, MDGL down 9.8% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL4N41J1II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDGL","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153136429","title":"Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1153136429","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153136429?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:05","pubTimestamp":1778076344,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.The sharp rise follows the company's release of first-quarter 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113827","title":"Madrigal Pharmaceuticals Price Target Maintained With a $620.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113827","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633113827?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:11","pubTimestamp":1778069460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 08:11 ET (12:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633718792","title":"Madrigal's Q1 product revenue jumps 127%, net loss widens on higher costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633718792","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633718792?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:26","pubTimestamp":1778066777,"startTime":"0","endTime":"0","summary":"Madrigal's Q1 product revenue jumps 127%, net loss widens on higher costsOverviewU.S. biopharma firm's Q1 product revenue rose 127% yr/yr on strong physician adoption of RezdiffraCompany posted wider ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633187891","title":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633187891","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633187891?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:19","pubTimestamp":1778066347,"startTime":"0","endTime":"0","summary":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118475","title":"Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118475","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118475?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:01","pubTimestamp":1778065312,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52315553/madrigal-pharmaceuticals-q1-eps-3-25-beats-3-60-estimate-sales-311-337m-beat-302-268m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633842291","title":"BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633842291","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633842291?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065248,"startTime":"0","endTime":"0","summary":"BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million\n\n\nMay 06 (Reuters) - Madrigal Pharmaceuticals Q1 operating income USD -92.723 million.\n\nQ1 operating expenses USD 404.06 million\nQ1 net income USD -94.391 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXE6F325:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633847301","title":"Madrigal Pharmaceuticals Inc: Mgl-2086 (Oral Glp-1) Phase 1 Trial on Track to Initiate in 2Q26","url":"https://stock-news.laohu8.com/highlight/detail?id=2633847301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633847301?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXE6F325:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","MDGL","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633840521","title":"Madrigal Pharmaceuticals Q1 EPS USD 3.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2633840521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633840521?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXE6F325:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633478184","title":"Madrigal Pharmaceuticals Q1 Operating Expenses USD 404.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633478184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633478184?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXE6F325:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDGL","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633184457","title":"Madrigal Pharmaceuticals Q1 Net Income USD -94.391 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633184457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633184457?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXE6F325:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0155},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0608},{"period":"6month","weight":-0.0091},{"period":"1year","weight":0.6966},{"period":"ytd","weight":-0.1238}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.116115},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction